Aurora A is a cell cycle protein kinase implicated in multiple human cancers, and several Aurora Aspecific kinase inhibitors have progressed into clinical trials. In this study, we report structural and cellular analysis of a novel biochemical mode of Aurora A inhibition, which occurs through reversible covalent interaction with the universal metabolic integrator coenzyme A (CoA). Mechanistically, the CoA 3'-phospho ADP moiety interacts with Thr 217, an Aurora A selectivity filter, which permits the formation of an unprecedented covalent bond with Cys 290 in the kinase activation segment, lying some 15 Å away. CoA modification (CoAlation) of endogenous Aurora A is rapidly induced by oxidative stresses at Cys 290 in human cells, and microinjection of CoA into mouse embryos perturbs meitoic spindle formation and chromosome alignment. Aurora A regulation by CoA reveals how targeting of Aurora A might be accomplished in the future by development of a 'doubleanchored' covalent inhibitor.
Introduction
Aurora kinases are Ser/Thr kinases that play well-documented roles in eukaryotes, where they control meiosis, mitosis and cell division (Carmena and Earnshaw, 2003) . Aurora kinases differ in their relative expression levels, stability and sub-cellular localization, the latter linked to subtle amino acid differences that dramatically affect biological distribution and function (Eyers et al., 2005 , Bayliss et al., 2004 , Fu et al., 2009 . In vertebrates, the Aurora family of protein kinases are grouped into two functionally distinct sub-families composed of Aurora A and Aurora B and C (Carmena et al., 2009 ). Aurora kinases contain a conserved C-terminal kinase domain, which phosphorylates substrates contained within a minimal R-X-S/T consensus motif (Sardon et al., 2010 , Haydon et al., 2003 . The Aurora kinase domain is itself regulated by a critical autophosphorylation event in the activation loop (Ohashi et al., 2006 , Bayliss et al., 2003 , Dodson et al., 2013 , which is associated with catalytic activation and timely execution of different phases of mitosis (Hegarat et al., 2011 , Tyler et al., 2007 , Scutt et al., 2009 , Yasui et al., 2004 and meiosis (Bury et al., 2017) . During the cell cycle, Aurora A has canonical roles in centrosome duplication, spindle bipolarity, chromosome segregation and spindle checkpoint maintenance (Courtheoux et al., 2018) , which together contribute to fundamental processes such as centrosomal and genomic stability and likely reflect the long-recognised oncogenic properties associated with overexpressed Aurora A (Bischoff et al., 1998) . Interestingly, Aurora A has also recently been implicated in the control of energy production in cancer cells through mitochondiral targeting (Bertolin et al., 2018) . In contrast, Aurora B is a centromeric kinase that is required for the spindle assembly checkpoint and ratelimiting for cytokinesis in cells, although it is also associated with cell transformation and a target for anti-proliferative therapy (Girdler et al., 2006 ). Aurora C is most highly expressed in germ cells, where it can functionally replace Auora B as a chromosome passenger protein (Carmena and Earnshaw, 2003) . Aurora A biology is controlled spatially via targeted subcellular localization mediated through the formation of dynamic protein complexes with non-catalytic binding partners such as TPX2 , Bayliss et al., 2003 , Wittmann et al., 2000 , TACC3 (Burgess et al., 2018) and NMYC (Richards et al., 2016) , which control distinct Aurora A signaling outputs relevant to cellular dynamics. Indeed, Aurora A/TPX2 holoenzyme complexes co-localise at the polar end of spindle microtubules, where Aurora A is maintained in dynamic pools alongside the mitoitc kinesin Eg5, which is localised by a C-terminal region of TPX2 (Eckerdt et al., 2008 , Zeng et al., 2010 . Allosteric Aurora A activation on the spindle is thought to occur by binding to microtubule-associated proteins (which are also Aurora A substrates) such as TPX2 and TACC3 (Dodson and Bayliss, 2012) . Mechanistically, Aurora A activation requires autophosphorylation of Thr 288 (and possibly Thr 287), which drives the kinase into the most catalytically-competent conformation (Walter et al., 2000 , Bayliss et al., 2004 .
Interestingly, the TPX2 complex also protects Aurora A from Thr 288 dephosphorylation by PP1 and PP2A phosphatases in vitro , Bayliss et al., 2004 , although accumulating evidence suggests that the PP6 Ser/Thr phosphatase is rate-limiting for mitotic dephosphorylation at this site in cells (Zeng et al., 2010) . In addition to TPX2, Aurora A is targeted to core protein cofactors, including the centrosomal protein Cep192, the mitotic entry factor BORA, the ciliary protein Pifo and the transcription factor NMYC (Joukov and De Nicolo, 2018) , whose interaction with a specific inactive Aurora A conformation is important for controlling NMYC stability in cells, and the basis for new approaches to target Aurora A output with drugs (Richards et al., 2017) .
Structural analysis of Aurora A confirms the importance of activation loop dynamics for activity and binding-partner interactions (Burgess et al., 2018) . Phosphorylation, as well as TPX2 binding, stabilise the activation segement in an appropriate conformation for catalysis, and distinct Aurora A conformations can also be induced and/or stabilised by a huge variety of chemical small molecules (Dodson et al., 2010 , McIntyre et al., 2017 , Pitsawong et al., 2018 , Tyler et al., 2007 , Scutt et al., 2009 , Damodaran et al., 2017 . Such compounds have been extremely useful to validate dozens of cellular Aurora A substrates (Tyler et al., 2005; Sardon, 2010) , which include other cell cycleregulated kinases such as PLK1 (Macurek et al., 2008 , Scutt et al., 2009 ). Aurora A is also regulated by distinct post-translational modifications, including acetylation. For example, the Ubiquitin ligase CHFR ubiquitinates Aurora A in vitro and in vivo, targeting it for proteosome-mediated degradation (Yu et al., 2005) . Interestingly, Aurora A is acetylated by arrest defective protein 1 (ARD1) acetyltransferase at lysines 75 and 125, and ARD1-mediated acetylation promotes cell proliferation and migration (Vo et al., 2017) .
In the clinical context, overexpression of Aurora A is frequently detected in various human malignancies, including leukemia, breast, prostate, and colon cancers (Keen and Taylor, 2004 , Bischoff et al., 1998 , Zhou et al., 1998 , and lower overall survival in patients with colorectal cancer correlates with increased levels of Aurora A (Goos et al., 2013) . For these reasons, Aurora A has been pursued for several decades as a target for the development of novel anti-cancer therapeutic agents, some of which have show potential in the clinic. Beginning with MLN8054 (Manfredi et al., 2007) , a number of potent, and highly selective, ATP-competitive small molecule inhibitors of Aurora A have been reported, with several advancing to phase II clinical trials, and MLN8237 (alisertib) proceeding to phase III evaluation after demonstrating activity in a variety of tumour settings (Tayyar et al., 2017 , D'Assoro et al., 2015 . Interestingly, while numerous ATPcompetitive and allosteric ligands for Aurora A have been developed, some of which can specifically target the highly similar Aurora A and Aurora B, no type IV (covalent) inhibitors of Aurora kinases have yet been reported, despite clinical successes with covalent tyrosine kinase inhibitors such as ibrutinib, afatinib and osimertinib. Coenzyme A (CoA) is essential for the viability of all living cells where it is a major regulator of cellular metabolism (Leonardi et al., 2005 , Theodoulou et al., 2014 . The CoA biosynthetic pathway is highly conserved in prokaryotes and eukaryotes and requires five enzymatic steps, involving sequential conjugation of pantothenic acid (vitamin B5), cysteine and ATP (Martinez et al., 2014 , Sibon et al., 2016 . The presence of a nucleotide moiety and a highly reactive thiol group permits broad diversity in biochemical reactions, which CoA employs to activate carbonyl-containing molecules and to generate covalent thioester derivatives such as Acetyl CoA, Malonyl CoA and 3-hydroxy-3methylglutaryl CoA. Intracellular levels of CoA and its thioester derivatives are tightly regulated by a variety of stimuli, including hormones, nutrients, metabolites and stresses (Leonardi et al., 2005 . The main rate-limiting enzyme in CoA biosynthesis is pantothenate kinase which initiates the biosynthetic pathway (Rock et al., 2000 , Dansie et al., 2014 .
Furthermore, the activity of the last enzyme in the pathway, CoA synthase, is regulated by extracellular stimuli and stress response (Zhyvoloup et al., 2003 , Breus et al., 2009 , Gudkova et al., 2012 , Breus et al., 2010 .
CoA and its thioester derivatives are strategically positioned at the crossroads of cellular anabolic and catabolic pathways, controling the Krebs cycle, ketogenesis, the biosynthesis of proteins, lipids and cholesterol, oxidation of fatty acids and degradation of amino acids. In additon, they are also involved in the regulation of gene expression and cellular metabolism via post-translational modifications, such as protein acetylation, butyrylation, malonylation and succinylation. Abnormal biosynthesis and homeostasis of CoA and its derivatives is associated with various human pathologies, including neurodegeneration, cancer, metabolic disorders and cardiac hypertrophy (McAllister et al., 1988 , Reibel et al., 1981 , Zhou et al., 2001 , Dusi et al., 2014 .
Protein CoAlation is a novel non-canonical function of CoA that involves covalent modification of cysteine residues in cellular response to oxidative and metabolic stress (Gout, 2018) . This recent discovery was only possible with the development of unique research tools and methodologies, which revealed protein CoAlation as a widespread and reversible PTM involved in cellular redox regulation (Malanchuk et al., 2015) . To date, more than one thousand proteins have been found to be CoAlated in a variety of prokaryotic and eukaryotic cells (Tsuchiya et al., 2017 , Tsuchiya et al., 2018 . Protein CoAlation occurs at a low level in exponentialy growing cells, but is strongly induced in reponse to various oxidising agents, including H2O2, diamide, menadione and t-butyl hydroperoxide. Protein CoAlation was shown to alter the molecular mass, charge, and activity of modified proteins, and to protect them from irreversible sulfhydryl overoxidation. These novel findings suggest that under normal growth conditions CoA mainly functions to produce metabolically active thioesters, while it may act as a low molecular weight antioxidant protecting protein cysteine thiols from irreversible overoxidation (Gout, 2018) .
The presence of exposed cysteine residues on the surface of proteins provides a simple, often reversible, mechanism for post-translational modification of cell signaling proteins in response to a wide variety of redox conditions. Most protein classes contain surface-exposed Cys residues, and for the protein kinase superfamily, this knowledge has been exploited to successfully develop covalent (usually irreversible) ATP-dependent kinase inhibitors with clinical utility (Lanning et al., 2014; Liu Q et al., 2010) . Interestingly, oxidative stress has marked effects on the cell cycle and proliferation (Chiu and Dawes, 2012) , and redox regulation of signaling-active components such as tyrosine phosphatases (Tonks, 2005) and cell cycle phosphatases such as CDC25 (Savitsky and Finkel, 2002) contribute to redox-regulated checkpoints. More recently, direct effects of oxidative stress on abnormal spindle dynamics have been correlated with Aurora A inhibition (Wang et al., 2017) . However, whether CoA regulates cell cycle-regulated protein kinases currently remains unknown.
In this study, we report direct Aurora A regulation through covalent interaction with CoA. We found that CoA is a specific ATP-competitive Aurora A inhibitor in vitro, and exploited a combination of biochemical, structural, mass spectrometry and cellular studies to confirm a preferential mode of CoA binding to the active kinase conformation. X-ray validation of the CoA binding mode confirms that it exploits Thr 217 in the ATP binding site, a locus that distinguishes Aurora A from Aurora B (Dodson et al., 2010 , to maintain a unique interaction with the 3'-phosphoADP moiety of CoA, positioning it for the unprecedented formation of a covalent bond between the pantetheine thiol and Cys 290, a remote residue found in the Aurora kinase activation loop. In support of this model, covalent modification of Aurora A by CoA was induced during cellular responses to oxidative stress, and microinjection of CoA perturbed spindle formation and chromosome alignment in vivo, causing potent cleavage arrest in fertilized mouse embryos. Taken together, our data reveal Aurora A as a novel target of the key metabolic regulator CoA, and open the door for the development of a new class of small molecules that exploits a 'dual-anchor' mechanism of inhibition bridging the Aurora A ATP-binding site and activation segment.
Results

Kinase profiling screen with coenzyme A reveals specific inhibition of Aurora A.
CoA and ATP share an ADP moiety, which we hypothesised might lead to a serendipitous modulation of the activity of protein kinases by CoA. We tested this notion in a human kinome-wide activity-based screen (MRC National Centre for Protein Kinase Profiling, University of Dundee).
Profiling of 117 protein kinases with CoA, dpCoA and ADP provided clear evidence that CoA is a relatively selective inhibitor for human Aurora A ( Fig. 1A and Table 1 ). Moreover, CoA inhibited Aurora A with marked selectivity (87% Aurora A inhibition at 100 µM, n=3) when compared to ADP, a very non-specific kinase inhibitor that operates based on its close similarity to ATP. Only a few other kinases, including the tyrosine kinases SRC and YES, were inhibited ≤50% by CoA under these conditions. Interestingly, inhibition of Aurora B by CoA was also detected (46% inhibition at 100 µM compound), while Aurora C was not present in the screen (Table 1) . Dephospho-CoA (dpCoA), which lacks the 3'-phosphorylated nucleotide, exhibited intermediate specificity between
CoA and ADP, raising the possibility that both the pantetheine and 3'-phosphate moieties of CoA could be important for optimal inhibition of Aurora A (Fig. 1A ). Further analysis confirmed that CoA inhibits active T288 phosphorylated (recombinant) Aurora A with an IC50 of approximately 5 µM in the presence of 5 M competing ATP in vitro (Fig. 1B ). Using CoA Sepharose as an affinity matrix, we confirmed that endogenous Aurora A present in exponentially growing HepG2 cells interacts specifically with conjugated CoA, when compared to beads alone ( Supplementary Fig. S1 ).
Furthermore, bound Aurora A was efficiently eluted from CoA Sepharose with an excess of CoA.
Next, we quantified the binding kinetics of CoA, dpCoA, ADP and ATP for catalytically active (T288 phosphorylated) and catalytically inactive (non-phosphorylated) forms of Aurora A. A Lanthascreen Eu Kinase FRET Binding Assay was employed to evaluate the interaction of CoA with Aurora A, and tease apart any molecular contributions made by the pantetheine tail and nucleotide 3'-phosphate.
We found that the displacement curves for CoA and dpCoA were biphasic, indicating the presence of two binding sites with higher and lower affinities towards CoA (Fig. 1C ). Bacterially expressed Aurora-A proteins auto-phosphorylate themselves to a varying degree, resulting in a heterogeneous mixture containing active and inactive Aurora-A (Scutt et al., 2009) . Importantly, treatment of the Aurora-A preparation with protein phosphatase 1, which results in T288 dephosphorylation , caused disappearance of the high affinity-binding site, confirming that this was related to the activation (phosphorylation) state of the kinase (Fig. 1D ). We next determined the affinity of interaction by titrating Aurora A with CoA, dpCoA and ADP, and compared them with values obtained from in vitro kinase (phosphotransferase) assays (Table 2) . Under the assay conditions used, the apparent IC50 for the interaction of active Aurora-A with CoA and dpCoA were 82 nM and 294 nM, respectively, whilst the IC50 value for ADP was approximately 177 µM. Taken together, these results clearly demonstrate that CoA and dpCoA preferentially bind to the active (T288-phosphorylated) form of Aurora A, and suggest an involvement of the pantetheine tail and the the 3'-phopshate of CoA in mediating a potentially specific interaction with Aurora A.
Biophysical and structural analysis of the Aurora A:CoA complex.
To confirm the interaction between CoA and Aurora A using intact mass spectrometry, we preincubated pT288 (phosphorylated) Aurora A with excess CoA, and observed a sub-stoichiometric shift for each of the differentially phosphorylated intact Aurora A species present in the preparation, consistent with the formation of phosphorylated Aurora A adducts, each containing a single molecule of CoA (Mr 767.54 Da, Fig. 1E ). We also evaluated effects of CoA and dpCoA on the gas phase conformation of Aurora A using Ion Mobility Mass Spectrometry (IM-MS), which is a new approach for probing kinase conformational dynamics (Byrne et al., 2016) . The calculated cross-sectional area of intact Aurora A (nm 2 ) in both 14 + and 15 + charge states increased significantly after pre-incubation with both CoA or dpCoA, consistent with their ability to bind to Aurora A and induce a conformational change. Comparative IM-MS of each complex confirmed species with larger cross-sectional areas than the control, whose formation was independent of the 3' phosphate group, predicting that Aurora A conformational changes are likely to be driven by covalent attachment of the CoA pantetheine tail ( Fig. 1F ).
To gain insights into the precise binding mode of the interaction between CoA and active Aurora A, we next determined the crystal structure of the complex to 2.5 Å resolution (Table 3 , Fig. 1G ). As predicted, CoA occupies the canonical ATP binding site of Aurora A, between the N-lobe and C-lobe of the kinase. Remarkably, the extended CoA pantetheine moiety stretches well away from the ATP site towards the kinase activation loop, forming a disulphide bond with the side chain of Cys 290 adjacent to the phosphorylated residue Thr 288 ( Fig. 1H ). Unexpectedly, the pantothenic acid moiety of CoA interacts with the tip of the Gly-rich loop (aa142-145) and displaces it from the position found in Aurora-A/ADP complexes, consistent with our IM-MS data. Interestingly, the 3' phosphate group of CoA is also ideally positioned to form a H-bond with the side chain of Thr 217, which is evolutionary conserved in vertebrate Aurora A, but not Aurora B (Dodson et al., 2010 .
Interestingly, our crystal structure of Aurora A/CoA is entirely consistent with independent molecular modelling of Aurora A bound to CoA, based on the previously determined structure of Aurora A/ADP ( Supplementary Fig. S2 ). The structure employed for modelling (PDB code 1OL7), was chosen based on previous knowledge that the side chain of Cys 290 is in a potentially suitable position to react chemically with the pantetheine tail of CoA. Importantly, most features of the experimental crystal structure were predicted by this model, including the specific interaction of the 3' phosphate group of CoA with the side chain of Thr 217. One exception is the experimentally up-shifted position of the Gly-rich loop in the presence of CoA, which was unexpected based on the model, where the Gly-rich loop resides in a canonical position, packed against the ADP 5' phosphate groups.
Aurora A is CoAlated on Cys 290 in vitro.
The electron density map unambiguously supports the formation of a covalent bond between the sulfur atoms in the side chain of Cys290 and pantetheine thiol of CoA ( Fig. 2A) . To investigate the contribution of this bond to the interaction, we employed a validated in vitro CoAlation assay (Tsuchiya et al., 2017) . Here, recombinant Aurora A was pre-incubated with CoA, and the reaction mixture was separated by SDS-PAGE under non-reducing conditions followed by immunoblotting with a monoclonal anti-CoA antibody. As shown in Fig Supplementary Fig. S3A ), confirming the co-existence of Thr 288-phosphorylated (active) Aurora A and Cys 290-CoA in vitro. We also examined whether binding of the 3'-phosphate ADP moiety of CoA to the Aurora A ATP binding pocket primes the pantetheine thiol for disulphide bond formation with Cys290 in the activation loop. In vitro CoAlation of Aurora A was carried out with 100 M CoA and increasing concentrations of ATP (0-10 mM). Aurora A CoAlation gradually decreased in the presence of increasing concentrations of ATP, and was completely abolished by inclusion of 1 mM DTT (Fig. 2C ). These observations suggest that occupancy of the ATP binding pocket by the 3'phosphate ADP moiety of CoA is a pre-requisite for covalent modification of Aurora A (see below). Aurora A has two surface-exposed cysteine residues present in the kinase domain: Cys290 in the activation loop and Cys393 in the C-terminal regulatory region .
Mutational analysis allowed us to demonstrate that covalent modification of the Cys290Ala mutant by CoA is dramatically reduced in comparison to wild-type Aurora A, while no binding was detected with the double Cys290/393Ala mutant ( Fig. 2D-F) . The dose-dependency of inhibition of active Aurora A by CoA was also examined in the absence and presence of a reducing agent ( Fig. 2G ). Aurora A was inhibited by CoA under both experimental conditions. However, the IC50 value (CoA) was an order of magnitude higher in the presence of DTT (47 μM), when compared to that obtained in the absence of DTT (5 μM). To explore the mode of regulation further, we tested the inhibitory effect of desulpho-CoA on Aurora A kinase activity. In this analogue of CoA, the reactive SH group at the end of the pantetheine tail is absent and unable to covalently modify Aurora A. Consistently, the dose response inhibition curve for desulpho-CoA was also shifted, resulting in a significantly higher IC50 value for Aurora A (160 μM), confirming the involvement of the CoA thiol group in the specific inhibition of Aurora A kinase activity (Fig. 2H ).
The role of Thr 217 in mediating a selective interaction between Aurora A and CoA.
We next sought to identify the basis of selectivity of CoA for Aurora A over other kinases. To do this, we focussed on the closely related Aurora A and B kinases, which share 70% sequence identity in the kinase domain (Fig. 3A) . The putative hydrogen bond between the -OH side chain of Thr 217 in Aurora A and the 3'-phosphate of the ribose ring of CoA ( Fig. 1H ) was of particular interest, since Thr 217 is known to contribute to the specificity of MLN8054, a selective Aurora A inhibitor (Sloane et al., 2010) , where the corresponding residue Glu 177 in Aurora B prevents compound binding, likely due to electrostatic repulsion , Dodson et al., 2010 . We compared covalent modification of Aurora A and Aurora B using an in vitro CoAlation assay (Fig. 3B, D) . This analysis revealed strong CoAlation of Aurora A, while Aurora B was CoAlated at an extremely low level under optimal Aurora A assay conditions (100 M CoA). Mutational analysis showed that the Thr217Glu mutant of Aurora A exhibits significantly reduced CoA binding compared to the wild-type kinase (Fig.   3C ). In contrast, Glu177Thr Aurora B mutant exhibited strong binding to CoA (Fig. 3E ). Together, these data indicate that both the 3'-phosphate ADP moiety and the thiol group of CoA are involved in mediating specificity-determining interactions with Aurora A via targeting of Thr 217 and Cys290 respectively.
Thermal shift analysis of the Aurora A/CoA interaction.
To probe thermal effects of CoA in the presence and absence of DTT, we profiled ligand binding in solution ( Fig. 3F ). WT Aurora A is phosphorylated and catalytically active, whereas D274N Aurora A cannot bind to ATP and therefore remains dephosphorylated after isolation from bacteria (Haydon et al., 2003) . C290A Aurora A lacks the thiol-containing Cys residue in the kinase activation segment ( Fig. 3A) , whereas T217E Aurora A mimics Aurora B by swopping a polar Thr for a charged Glu (see above). Thermal melting profiles for each protein were obtained in the presence and absence of DTT and ATP, CoA or the Aurora A inhibitor MLN8237. Binding of ATP, CoA and MLN8237 induced a marked change in thermal stability of WT Aurora A, which was dependent on non-reducing conditions in the case of CoA, and entirely consistent with findings with Aurora A isolated from human cells (Fig. 2B ). Interestingly, CoA was still able to interact with kinase-dead D274N (inactive) Aurora A in a DTT-dependent manner, although its interaction with Mg-ATP was severely blunted, as expected (green bars). In contrast, C290A Aurora A bound to ATP, but was deficient in CoA-induced thermal stabilization (red bars). Finally, a CoA-induced thermal shift was completely abolished in the T217E Aurora A mutant, in contrast to those of either ATP or MLN8237, reiterating the importance of a Thr at this position for CoA binding.
Binding of TPX2 protects Aurora A from covalent modification and inhibition by CoA.
In vertebrates, TPX2 enhances Aurora A autophosphorylation and protects it from dephosphorylation by phosphatases. Biochemical and crystallographic analyses have revealed the molecular mechanism by which the N-terminal fragment of TPX2 (residues 1-43) interacts with Aurora A, and locks it in a stable active conformation, also protecting it from dephosphorylation by PP1 phosphatase (Fig. 4A, left) . Protection from enzymatic dephosphorylation occurs because the phosphate group of Thr 288 is buried in the TPX2-bound form (Bayliss et al., 2003) . The side chain of Cys290 is also buried in the TPX2-bound, active conformation of Aurora A, and furthermore it points away from the ATP binding side, whereas the thiol group is exposed in structures of active Aurora A obtained in the absence of TPX2 in which CoA (Fig. 4A , middle) or ADP (Fig. 4A, right) are bound. We therefore investigated whether the inhibitory effect of CoA on Aurora A was modulated by TPX2. Dose inhibition curves of Aurora A by CoA were generated in the presence and absence of TPX2. As shown in Fig. 4B , the presence of the TPX2 1-43 fragment in an in vitro kinase assay completely abrogated the inhibitory effect of CoA on Aurora A. However, pre- incubation of Aurora A with CoA prevented TPX2-induced kinase activation in a DTT-sensitive manner (Fig. 4C) . These findings indicate that binding of TPX2 protects Aurora A not only from dephosphorylation of Thr 288 by phosphatases, but that it can also prevent covalent modification (and therefore inhibition) of the kinase by CoA.
Oxidative stress induces Aurora A CoAlation in cells.
Extensive protein CoAlation is observed in mammalian cells and tissues exposed to oxidative and metabolic stress (Tsuchiya et al., 2017) . We therefore examined whether covalent modification of Aurora A by CoA is induced in cells after exposure to various oxidative stresses (Tsuchiya et al., 2017) . We exploited HEK293/Pank1 cells, which stably overexpress pantothenate kinase 1 (Pank1β), the major rate-limiting enzyme in CoA biosynthesis (Tsuchiya et al., 2017) . It has been shown previously that Pank1β overexpression induces a significant increase in CoA biosynthesis.
These cells are also ideal for evaluating protein CoAlation in cellular response to oxidative and metabolic stress (Tsuchiya et al., 2017) . Accordingly, cells were transiently transfected with plasmids encoding N-terminally FLAG-tagged Aurora A and Aurora B, and then treated with 500 μM H2O2 prior to lysis. Immunoprecipitation of transiently expressed FLAG-tagged proteins followed by immunoblotting with anti-CoA antibody revealed specific CoAlation of Aurora A in cells after exposure to H2O2, but Aurora B was poorly CoAlated (Fig. 5A) . To map the site(s) of Aurora A CoAlation, transiently overexpressed FLAG-Aurora A was immunoprecipitated from cells exposed to H2O2, processed and analysed by LC-MS/MS. This analysis revealed a CoAlated Aurora A peptide derived from the activation segment with the sequence TTLC 290 GTLDYLPPEMIRGR, confirming covalent modification in cells ( Supplementary Fig. S3B ), and consistent with in vitro CoAlation of recombinant Aurora A (Fig. 2B ). Next, Aurora A CoAlation was examined in cells exposed to a diverse range of oxidising agents. As shown in Fig. 5B , CoAlation of transiently expressed Aurora A was strongly induced in cells treated with diamide and to a lesser extent after exposure to menadione or phenylarsine oxide (PAO). It was recently reported that ROS-induced cell cycle arrest promotes hyperphosphorylation of Aurora A leading to abnormal mitotic spindle assembly and significant mitotic delay (Wang et al., 2017) . Therefore, we examined phosphorylation of Aurora A at Thr 288 by probing the same immunoprecipitation samples with anti-pT288 antibody. We confirmed that treatment of cells with H2O2 and menadione promoted an increase in Aurora A phosphorylation at Thr 288. We also observed a strong induction of phosphorylation with PAO, when compared to control cells (Fig. 5B ). Taken together, these results allow us to propose a simple model for regulation of Aurora A by oxidative stress in cells (Fig. 5C ). In exponentially growing cells, Aurora A carries out many of its cellular functions by using ATP as substrate for protein phosphorylation. The binding of CoA to the Aurora A ATP binding pocket via the ADP moiety is effectively outcompeted by ATP (Fig.   5C, left panel) . In contrast, exposure of cells to oxidative stress induces covalent binding of CoA to phosphorylated Aurora A (Fig. 5C, right panel) , which is accompanied by a loss of catalytic activity and altered cell signaling.
Microinjection studies in mouse oocytes.
It has been established that functional (catalytically-active) Aurora A is essential for normal spindle formation during mouse oocyte maturation (Bury et al., 2017 , Saskova et al., 2008 . To investigate the effect of CoA on Aurora A functions in vivo, we employed a well-established model for microinjecting CoA and related molecules into immature murine oocytes. Oocytes arrested at the GV stage were injected with different concentrations of CoA. 17 hours after GV release, oocytes were fixed and stained for -tubulin (green) and DNA (blue) to observe effects on spindle formation.
We found that microinjection of CoA markedly increased the number of oocytes with atypical spindles and misaligned chromosomes in a dose-dependent manner ( Supplementary Fig. 4A) . Our in vitro studies demonstrated the importance of both the pantetheine tail and the 3' phosphate of CoA in mediating a high-affinity interaction with Aurora A (Fig. 1) . We therefore examined the effect of injected CoA or different compounds representing integral parts of the CoA molecule to cause abnormal spindle formation and misalignment of chromosomes in mouse oocytes. We found that CoA, but not pantetheine, ADP or AMP, was capable of disrupting bipolar spindle formation and chromosome alignment in vivo ( Supplementary Fig. 4B ). These data confirm that the pantetheine tail is a requirement for the inhibitory effects of CoA in mouse oocytes. Taken together, our in vivo oocyte microinjection studies provide strong evidence that an increase in cellular CoA has the potential to deregulate spindle formation and the alignment of chromosomes in oocytes, causing meiotic cleavage arrest.
Discussion
Binding partners and post-translational modifications regulate the activity of Aurora A by switching it between inactive and active conformations (Levinson, 2018) . The intrinsic catalytic activity of Aurora A is low prior to mitosis, and activation involves autophosphorylation of Thr 288 in the activation loop, which is promoted through interaction with microtubule-associated proteins such as TPX2 and TACC3. In this study, CoA is identified as a key metabolic molecule that binds and inhibits Aurora A activity, potentially as part of the cellular response to oxidative stress. Aurora A CoAlation was not observed in exponentially growing cells, but it was significantly induced as part of the cellular response to oxidative stresses. Based upon our 'dual-anchor' inhibitory model (Fig. 5C ), Aurora A CoAlation is initiated by anchoring the ADP moiety of CoA to the ATP-binding pocket of the oxidized form of Aurora A, which involves a selectivity-determining interaction between the 3'-phosphate ADP moiety of CoA and Thr 217. Wedging of the ADP moiety then positions the flexible pantetheine tail of CoA with the thiol group in close proximity for covalent bond formation with Cys 290 in the Aurora A activation segment, two residues C-terminal from the regulatory phosphorylated Thr 288 residue.
We speculate that under oxidative stress, covalent binding of the pantetheine thiol to Cys 290 keeps the ADP moiety firmly anchored to the ATP binding pocket, making it inaccessible to ATP, and preventing phosphotransferase activity. The "dual anchor" mechanism of locking the kinase in an inactive state therefore makes CoA a more potent and selective endogenous inhibitor of Aurora A when compared to Aurora B and other protein kinases.
What is the biological function of Aurora A CoAlation?
In addition to an inhibitory effect on Aurora A activity, CoAlation at Cys 290 may serve other regulatory purposes. First, CoA modification might protect Cys 290 from overoxidation, which may lead to an irreversible loss of function and subsequent inactivation and/or degradation of Aurora A. The widespread ability of CoA to act as a low-molecular-weight antioxidant in response to oxidative and metabolic stress in prokaryotic and eukaryotic cells has been recently demonstrated (Tsuchiya et al., 2017 , Tsuchiya et al., 2018 . In these studies, in vitro CoAlation of the catalytic Cys 151 in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was shown to protect this essential glycolytic enzyme against irreversible overoxidation and the associated loss of activity. It remains to be seen whether oxidation of Cys 290 in Aurora A to sulphenic acid (which is reversible) facilitates covalent modification by CoA via a disulphide-exchange mechanism, protecting this highly susceptible thiol from irreversible overoxidation. Secondly, covalent modification of Cys 290 by CoA may modulate the phosphorylation status of Thr 288, which is critical for Aurora A catalytic activity. Previous studies reported differential sensitivity of Thr 288 to dephosphorylation by phosphatase complexes of the phosphoprotein phosphatase (PPP) family. An intriguing possibility is that redox-induced covalent linkage of CoA to Cys 290, which is directly adjacent to Thr 288, may prevent the binding of phosphatases that control the dephosphorylation of Thr 288. In support of this hypothesis, we found that phosphorylation of Aurora A at Thr 288 is significantly increased under oxidative stress induced by H2O2, menadione and PAO. However, it is also possible that a build-up of phosphorylated Aurora A is due to the fact that CoA is a more efficient inhibitor of the phosphorylated form of Aurora A, meaning that it spares Aurora A autophosphorylation, or that CoAlation of Aurora A changes recognition of the protein by the T288 phosphospecific antibody.
An involvement of CoA, a fundamental metabolic integrator in the regulation of Aurora A, provides new insight into our understanding of regulatory mechanisms of cell cycle progression mediated by metabolic adaptation to oxidative stress. Energy flow and biosynthetic processes are tightly regulated during the cell cycle. CoA plays a critical role in generating a diverse range of metabolically active thioester derivatives (including Acetyl-CoA, HMG-CoA, Malonyl-CoA and Acyl-CoA), which function as driving forces for generating ATP, the biosynthesis of macromolecules and the regulation of gene expression via protein acetylation. The presence of a highly reactive thiol group in CoA and its potential involvement in redox regulation has intrigued researchers for many decades, but progress in this field of study has been hampered by a lack of precise research tools and methodologies. Our findings are consistent with novel functions of CoA in the cellular response to oxidative and metabolic stress, which involves covalent attachment of this coenzyme to redoxsensitive Cys residues (Tsuchiya et al., 2017) . CoA levels also change during early embryogenesis in Xenopus laevis, consistent with shifts in energy usage and perhaps CoAlation before and after the midblastula transition . Protein CoAlation is therefore emerging as an important post-translational modification implicated in redox regulation of a diverse range of proteins (Gout, 2018) , including redox-controlled protein kinases (Corcoran and Cotter, 2013) .
Our work also demonstrates a hitherto unappreciated role for CoA in the regulation of Aurora A activity in cellular response to oxidative stress, and also suggests the potential importance of this form of regulation for other protein kinases that possess cysteine residues within the activation segment, or elsewhere (Zhao et al., 2017) . This includes the Aurora A-related basophilic Ser/Thr kinase PKA, for which inhibition by CoA was not detected in vitro. However, the reversible glutathionylation of Cys 199, equivalent to Cys 290 in Aurora A, has previously been demonstrated (Humphries et al., 2002,) and correlated with functional roles for the Cys 199 redox status in controlling T-loop phosphorylation at the adjacent Thr 197 site in PKA, equivalent to Thr 288 in Aurora A (Humphries et al., 2005 , Humphries et al., 2007 . In addition to Aurora A, CoA also modestly inhibits several unrelated protein kinases, including SRC, YES, BTK and FGFR1 (Table 1) . However, none of these tyrosine kinases contains a Cys residue in the activation segment, and it remains to be seen whether covalent modification of these kinases by CoA occurs in cells, and if so, whether it is also induced by oxidative stress. In the case of CoA, our data suggest that the "dual anchor" inhibitory mechanism in Aurora A permits precise spatial communication between the ATP-binding site and the activation loop, explaining the very high degree of specificity for CoAlation of Aurora A and preventing high-affinity interaction with even closely-related kinases, such as Aurora B.
Significance
Our findings raise the interesting possibility that new covalent approaches can be developed to target Aurora A, or other kinases possessing Cys residues in the activation segment, with small inhibitory molecules. This dual targeting mechanism might be the basis of a new approach for design of specific, and potentially irreversible, Aurora A small molecule inhibitors, with long-time target engagement in cells. The majority of protein kinase (including Aurora A) inhibitors are currently ATP competitive (non-covalent) inhibitors, which are designed to gain at-least some selectivity through the recognition of unique features of conformation-specific ATP-binding pockets. However, there has been a resurgence of interest in generating covalent compounds targeting Cys residues in drug targets, most notably RAS (Ostrem et al., 2013) , previously considered undruggable. Moreover, biochemical tool compounds (Zhang et al., 2016 , Ocasio et al., 2018 and clinical inhibitors covalently targeting oncogenic kinase, are enjoying significant clinical success (Zhao and Bourne, 2018) .
However, one of the liabilities of such compounds is the appearance of drug resistance, caused by point mutations in the Cys residue at the covalent drug interface. In this study, we report a new 'dualmode' of Aurora A inhibition by the metabolic integrator CoA, which also reveals how specific targeting of kinases might be accomplished with a distinct class of irreversible inhibitor, whose ability to covalently trap kinases in an inhibitory conformation could represent a new way of tuning signaling outputs. 
Figure Legends
Materials and Methods
Reagents and chemicals
The generation and characterization of the monoclonal anti-CoA antibody 1F10 has been described previously (Tsuchiya et al., 2017) . All common chemicals and biochemicals were obtained from Sigma-Aldrich unless otherwise stated, including CoA, dpCoA, dsCoA, ATP, and ADP. The following antibodies were employed: mouse anti-CoA antibody; mouse anti-FLAG M2 antibody (Sigma-Aldrich); rabbit anti-Aurora A and anti-Aurora B antibodies (Merck-Millipore); rabbit anti-pT288 Aurora A (Cell Signaling Technology) , Alexa Fluor 680 goat anti-mouse IgG H&L (Life Technologies) and IRdye 800 CW goat anti-rabbit IgG H&L (LI-COR Biosciences).
Kinase profiling screen and Aurora A IC50 determination
Profiling of 117 protein kinases with CoA, dpCoA and ADP was carried out at the International Centre 
In vitro Aurora A kinase assay
Aurora A kinase activity was assayed by measuring incorporation of  33 P-ATP into myelin basic protein (Sigma). Purified recombinant protein (100 ng) was incubated at room temperature for 30 min in a total volume of 15 μl containing 50 mM HEPES pH 7.5, 10 mM MgCl2, 1mM EGTA, 0.05%
Brij-35, 0.5 mg/ml myelin basic protein, and 5 μM  33 P-ATP (100-10,000 dpm/pmol). The reaction was stopped by spotting the reaction mixture onto squares of P81 phosphocellulose ion exchange paper (Whatmann), which were then immersed in 1.5% (v/v) phosphoric acid. After washing twice in 1 % phosphoric acid followed by two washes in distilled water, the papers were air dried and radioactivity was counted by a scintillation counter and recorded by Quantasmart version 2.03.
In vitro CoAlation Assay
For CoAlation assays, 0.5 µg of purified recombinant preparations of wild type and mutant forms of His-Aurora A (Cys290Ala; Cys393Ala, Cys290/393Ala, Thr217Glu) and His-Aurora B (Glu161Thr)
were incubated with a mixture of oxidised and reduced forms of CoA (CoASH and CoASSCoA, 1 mM final) in 20 mM Tris-HCl, pH 7.5 for 30 min at RT. The reaction was stopped by adding SDS gelloading buffer without DTT, but containing 10 mM NEM. To examine whether binding of the 3'phosphate ADP moiety of CoA to the Aurora A ATP binding-pocket co-ordinates the pantetheine thiol for disulphide bond formation with Cys290, the in vitro CoAlation assay was carried out with 100 M CoA and increasing concentrations of ATP (0-10 mM).
CoA Sepharose pull-down assay
Exponentially growing HepG2 cells were lysed on ice in buffer, containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 50 mM sodium fluoride (NaF), 5 mM tetra-sodium pyrophosphate (Na4P2O7) 
Lanthascreen Eu Kinase FRET Binding Assay
A Lanthascreen Eu Kinase FRET Binding Assay (Invitrogen) was employed to determine IC50 values for the interaction of Aurora A with CoA, dpCoA, ATP, and ADP. In this assay, we used bacterially expressed His-Aurora A in active and inactive (PP1-treated, pT288 dephosphorylated) states. reaction mix was incubated for 1 h at room temperature. The signal was measured at 665/620 nm emission ratio using BMG LABTECH plate reader (PHERAstar). All assays were performed using duplicates. The 11-point response curves were generated using GraphPad Prism software from the inhibition data generated.
Plasmids and Protein purification for Differential Scanning Fluorimetry (DSF)
For enzyme and DSF assays, full-length human Aurora In this study, mouse oocytes arrested at the GV stage were injected with different concentrations of CoA (0.15-5 mM). Since the commercial preparation of CoA used for microinjection contained 3 moles of lithium ion per mole of CoA, control oocytes were injected with equivalent amount of LiCl.
In a separate study, arrested oocytes were injected with 3 mM CoA, ADP, AMP, 3'-5'-ADP and pantetheine. To examine the effect of injected compounds on spindle formation, oocytes were fixed 17 hours after GV release and stained for alpha-tubulin (green) and DNA (blue)
Intact Mass Spectrometry
To generate CoA complexes with Aurora A, 10 M WT Aurora A was incubated with 1 M Coenzyme A for 15 minutes at room temperature. To evaluate the interaction, intact complexes were desalted using a C4 desalting trap (Waters MassPREP™ Micro desalting column, 2.1 × 5 mm, 20 μ m particle size, 1000 Å pore size). Aurora A was eluted with 50 % (v/v) MeCN, 0.1 % (v/v) formic acid. Intact mass analysis was performed using a Waters nano ACQUITY Ultra Performance liquid chromatography (UPLC) system coupled to a Waters SYNAPT G2, as described . Samples were eluted from a C4 trap column at a flow rate of 10 µL/min using three repeated 0-100 % acetonitrile gradients. Data was collected between 400 and 3500 m/z and processed using MaxEnt1 (maximum entropy software, Waters Corporation).
Ion Mobility
IM-MS analysis was performed on a Waters Synapt G2-Si instrument. Aurora A was buffer exchanged into 50 mM NH4OAc (LC grade, Sigma) as previously described (Byrne et al., 2016) . Typically, 1-3 µl of 2-5 µM sample was analyzed using borosilicate emitters (Thermo ES 387). Spraying voltage was adjusted to 1.1 -1.8 kV, sampling cone was 20 V. Pressure in the travelling wave (T-wave) ion mobility cell was 2.78 mbar (nitrogen), wave height was kept at 30 V, wave velocity at 750 m/s. In order to experimentally determine collision cross section (CCS), drift time through the T-wave mobility cell was performed using β-lactoglobulin A (Sigma L7880), avidin (Sigma A9275), transthyretin (Sigma P1742), concanavalin A (Sigma C2010) and serum albumin (Sigma P7656) according to standard protocols.
The exact hard sphere scattering (EHSS) model implemented in the Mobcal software was used to calculate CCS values on the basis of X-ray structures, as described previously (Byrne et al., 2016) .
Mass spectrometry and data processing
In vitro CoAlated His-Aurora A or immunoprecipitated FLAG-Aurora A were digested with sequencing grade trypsin (Promega). After heat-inactivation of trypsin, CoAlated peptides were immunoprecipitated with anti-CoA antibody cross-linked to Protein G Sepharose. 
Redox-induced interaction between Aurora A and CoA is mediated by Thr217 and Cys290
C-lobe C IP: anti-FLAG WB: anti-FLAG 37kDa -50kDa -
